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Neurodevelopmental expression profile of dimeric and monomeric group
1 mGluRs: relevance to schizophrenia pathogenesis and treatment
Abstract

Group 1 metabotropic glutamate receptors (mGluR1/mGluR5) play an integral role in neurodevelopment
and are implicated in psychiatric disorders, such as schizophrenia. mGluR1 and mGluR5 are expressed as
homodimers, which is important for their functionality and pharmacology. We examined the protein
expression of dimeric and monomeric mGluR1α and mGluR5 in the prefrontal cortex (PFC) and
hippocampus throughout development (juvenile/adolescence/adulthood) and in the perinatal phencyclidine
(PCP) model of schizophrenia. Under control conditions, mGluR1α dimer expression increased between
juvenile and adolescence (209-328%), while monomeric levels remained consistent. Dimeric mGluR5 was
steadily expressed across all time points; monomeric mGluR5 was present in juveniles, dramatically declining
at adolescence and adulthood (−97-99%). The mGluR regulators, Homer 1b/c and Norbin, significantly
increased with age in the PFC and hippocampus. Perinatal PCP treatment significantly increased juvenile
dimeric mGluR5 levels in the PFC and hippocampus (37-50%) but decreased hippocampal mGluR1α
(−50-56%). Perinatal PCP treatment also reduced mGluR1α dimer levels in the PFC at adulthood (−31%).
These results suggest that Group 1 mGluRs have distinct dimeric and monomeric neurodevelopmental
patterns, which may impact their pharmacological profiles at specific ages. Perinatal PCP treatment disrupted
the early expression of Group 1 mGluRs which may underlie neurodevelopmental alterations observed in this
model.
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Neurodevelopmental Expression
Profile of Dimeric and Monomeric
Group 1 mGluRs: Relevance to
Schizophrenia Pathogenesis and
Treatment
Jeremy S. Lum1,2,3, Francesca Fernandez1,2,3,4, Natalie Matosin1,2,3,5, Jessica L. Andrews1,2,3,
Xu-Feng Huang1,2,3, Lezanne Ooi1,6 & Kelly A. Newell1,2,3
Group 1 metabotropic glutamate receptors (mGluR1/mGluR5) play an integral role in
neurodevelopment and are implicated in psychiatric disorders, such as schizophrenia. mGluR1 and
mGluR5 are expressed as homodimers, which is important for their functionality and pharmacology.
We examined the protein expression of dimeric and monomeric mGluR1α and mGluR5 in the prefrontal
cortex (PFC) and hippocampus throughout development (juvenile/adolescence/adulthood) and in
the perinatal phencyclidine (PCP) model of schizophrenia. Under control conditions, mGluR1α dimer
expression increased between juvenile and adolescence (209–328%), while monomeric levels remained
consistent. Dimeric mGluR5 was steadily expressed across all time points; monomeric mGluR5 was
present in juveniles, dramatically declining at adolescence and adulthood (−97–99%). The mGluR
regulators, Homer 1b/c and Norbin, significantly increased with age in the PFC and hippocampus.
Perinatal PCP treatment significantly increased juvenile dimeric mGluR5 levels in the PFC and
hippocampus (37–50%) but decreased hippocampal mGluR1α (−50–56%). Perinatal PCP treatment
also reduced mGluR1α dimer levels in the PFC at adulthood (−31%). These results suggest that Group
1 mGluRs have distinct dimeric and monomeric neurodevelopmental patterns, which may impact their
pharmacological profiles at specific ages. Perinatal PCP treatment disrupted the early expression of
Group 1 mGluRs which may underlie neurodevelopmental alterations observed in this model.
Glutamate is the primary excitatory neurotransmitter in the central nervous system. It plays a vital role in
neurodevelopmental processes, including synaptic plasticity, neurite outgrowth and neuronal migration1,2.
Glutamate signals through the ionotropic (N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl4-isoxazolepropionic acid (AMPA) and kainate) and metabotropic (mGluR 1–8) families of glutamate receptors.
mGluRs are categorised into 3 groups, based on their sequence homology, G-protein coupling and pharmacology3.
Group 1 mGluRs, which consist of mGluR1 and mGluR5, are expressed in the brain from early development
and are implicated in the pathogenesis and treatment of several neurodevelopmental and psychiatric disorders,
including schizophrenia (for review see ref. 4). mGluR1 is commonly found as 2 isoforms (mGluR1α, mGluR1β) ,
which differ in their C-terminal and display different signalling kinetics, with the shorter variant, mGluR1β, displaying slower Ca2+ kinetics than mGluR1α5,6. mGluR5 is most commonly spliced as 2 variants (mGluR5a and
mGluR5b), which differ by a 33 amino acid insert at the C-terminal and are neurodevelopmentally regulated7, yet
show no pharmacological differences8.
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The neurodevelopmental protein expression of Group 1 mGluRs has previously been reported in rodents5–7.
However, many of these studies were performed before the discovery of mGluR homodimerisation and focused
only on the monomeric form of these receptors. Evidence has shown that Group 1 mGluR homodimers are
joined via a disulphide bond at the Venus fly trap domain located on the N-terminus9. Accordingly, it has been
repeatedly reported that under non-reducing electrophoresis conditions, Group 1 mGluRs primarily migrate at
twice the expected molecular weight7,9,10, consistent with their expression as constitutive homodimers. While,
there is in vitro evidence of functional mGluR1/5 heterodimers11, there is still a lack of evidence for this in vivo.
Furthermore, the functional and pharmacological consequences of Group I mGluR heteromeric complexes
are still not understood. Recently, El Moustaine and colleagues12, highlighted the functional significance of
mGluR homodimerisation, demonstrating that although dimerisation of mGluRs is not required for G-protein
coupling, dimerisation is necessary for agonist-induced activation, rendering the monomeric form inactive to
agonist-induced activation. Furthermore, positive allosteric modulator (PAM) compounds, which are being
investigated as a novel schizophrenia treatment, act as full agonists on mGluR monomers in the absence of glutamate, with dimeric arrangement of mGluRs vital for controlling PAM-induced agonist-like activity.
Administration of NMDA receptor (NMDAR) antagonists, such as phencyclidine (PCP), during early
post-natal development in rodents is widely used to investigate the neurodevelopmental aspects of schizophrenia13.
We and others have shown that this model alters development of the glutamatergic system including the ionotropic NMDA receptor14–17. However, it is unclear whether perinatal NMDA receptor antagonism, impacts the
neurodevelopmental expression of Group 1 mGluRs. These receptors are purported to be involved in the development of schizophrenia18–22 and we have recently reported that the expression of these receptors are altered in the
prefrontal cortex (PFC) and hippocampus in postmortem tissue from schizophrenia subjects23–25. Understanding
the developmental expression profile of Group 1 mGluRs may provide insight into their role in the development
of neuropsychiatric disorders at critical neurodevelopmental time points. Therefore, the present study aimed to
measure the native dimeric and monomeric forms of mGluR1αand mGluR5 throughout normal neurodevelopment and following perinatal PCP treatment, an established rodent model of schizophrenia. In addition, we
examined two key regulators of Group I mGluRs, Homer1b/c and Norbin (Neurochondrin-1)26. To our knowledge, this is the first measure of Homer1b/c and Norbin throughout neurodevelopment in rats. Homer1b/c and
Norbin increase Group 1 mGluR cell-surface expression and signalling, including the capacity of mGluR5 and
NMDA receptor co-activity27,28. Furthermore, Homer1c expression has shown to reduce mGluR5 dimerisation.
We and others have reported altered protein expression of both Homer1b/c and Norbin in the PFC and hippocampus of schizophrenia subjects23–25,29,30. Investigation of Homer1b/c and Norbin expression through neurodevelopment, in particular, in a schizophrenia relevant paradigm, may provide a deeper understanding into
potential underlying mechanisms for changes to Group 1 mGluRs localisation and activity.

Results

Group 1 mGluRs (dimeric and monomeric forms) were examined at postnatal days (PN)12, 35 and 96, corresponding to juvenile, adolescent and adult time points, which are key periods for the emergence of psychiatric disorders15,31. mGluR1αand mGluR5 monomeric and dimeric proteins were clearly identified in the rat
PFC and hippocampus at all time points (Fig. 1A,B, respectively), with the exception of the mGluR5 monomer,
which showed relatively low expression at PN35 and PN96 in both regions. mGluR1αand mGluR5 presented
as two dimer bands (~270–280 kDa) and a single monomer band (~150 kDa), as previously reported9,32,33. The
two dimeric bands were quantified as the dimer; these bands have previously been reported using alternative
mGluR1αand mGluR5 antibodies, and have been confirmed as specific, using respective knockout mice33,34. The
sums of the dimer and monomer densitometry values were taken to equal total mGluR1αand mGluR5.

mGluR1α total, dimeric and monomeric expression in the PFC and hippocampus.

Two-way
ANOVAs revealed significant main effects of age on mGluR1αprotein expression in the PFC (Total: F2,28 =  55.086;
p < 0.001; Dimer: F2,29 =  93.889; p < 0.001; Monomer: F2,26 =  12.104; p < 0.001). Post-hoc analyses in control rats
revealed total mGluR1αexpression significantly increased from PN12 to PN35 (160%, p < 0.001) with no significant difference between PN35 and PN96. Dimeric mGluR1αexpression similarly increased from PN12 to PN35
in control rats (209%, p < 0.001) followed by a modest increase from PN35 to PN96 (26%, p =  0.049). mGluR1α
monomer levels showed a general trend toward increased expression at each developmental time point in the
control group, yet a significant difference was only observed between PN12 and PN96 (117%, p =  0.044) (Fig. 2).
There was a main effect of PCP treatment on dimeric mGluR1α (F1,29 =  12.107; p = 0.002) and age x treatment
interactions on total (F2,28 =  5.066; p = 0.013) and dimeric mGluR1αprotein expression in the PFC (F2,29 =  4.244;
p = 0.024); PCP treated rodents displayed a reduction in total (−31%, p = 0.018) and dimeric (−31%, p =  0.006)
mGluR1αexpression compared to saline treated rats at the PN96 time point only (Fig. 2). There was no effect of
PCP treatment on mGluR1 monomer.
In the hippocampus mGluR1αtotal and dimer expression, but not monomer, were significantly affected
by age (Total: F2,29 =  26.946, p < 0.001; Dimer: F =  2,30 =  36.222, p < 0.001; Monomer: F2,30 =  0.800, p =  0.459).
Post-hoc analysis showed mGluR1α protein levels significantly increased between PN12 and PN35 in control rats (Total: 109%, p = 0.007; Dimer: 328%, p < 0.001). This was followed by a decrease from PN35-PN96,
which only reached significance for the dimer (Total: −38%, p =  0.095; Dimer: −48% p = 0.024; Fig. 2). There
was no main effect of PCP treatment on mGluR1αprotein expression in the hippocampus (Total: F1,29 =  0.006;
p = 0.939; Dimer: F1,30 =  0.003; p = 0.959), although there was a trend towards a significant treatment effect on
mGluR1αmonomer levels (F1,30 =  3.870; p = 0.058), in which PCP treatment resulted in an overall 21% reduction
in mGluR1αmonomer expression. There were no age x treatment interactions for mGluR1αtotal (F2,29 =  1.946;
p = 0.161), dimer (F2,30 =  0.733; p = 0.489) or monomer (F2,30 =  0.635;p = 0.537) protein levels. However, visual
inspection of the means suggested treatment effects on mGluR1αprotein expression at the PN12 and PN96
Scientific Reports | 6:34391 | DOI: 10.1038/srep34391

2

www.nature.com/scientificreports/

Figure 1. Neurodevelopmental and perinatal PCP-induced effects on Group 1 mGluR protein expression.
Representative immunoblot images of mGluR1αand mGluR5 from saline (S) and perinatal phencyclidine
(P) treated rats at postnatal days (PN) 12, 35 and 96 in the (A) prefrontal cortex and (B) hippocampus. NB:
Membranes were exposed to film for varying times to optimise images for dimer and monomer quantification.
Immunoblot values were normalised to β-actin. Immunoblots of mGluR1αand mGluR5 produced two bands
at 270 and 280 kDa, which has been previously reported33,34 and these were quantified together as the dimer. The
band corresponding to 150 kDa was quantified as the monomeric form of mGluR1αand mGluR5, respectively.
NB: Immunoblots of mGluR1αin the hippocampus showed a band at approximately 140kda, which was not
observed in the PFC. This band was deemed as non-specific and therefore not quantified.

time points (Fig. 2). Exploratory post-hoc analyses at the PN12 time point revealed total and dimeric mGluR1α
levels were significantly reduced in perinatal PCP treated rats at PN12 (−40%, t10 =  3.240; p =  0.009 and −56%,
t10 =  4.509 p = 0.001, respectively), however mGluR1αmonomer levels did not reach significance (t10 =  1.470;
p = 0.172). Furthermore, monomeric mGluR1αlevels were reduced at PN96 in perinatal PCP treated rats (−32%,
t10 =  2.560; p = 0.028) compared to controls, however this finding did not withstand Bonferroni correction for
multiple testing.

mGluR5 total, dimeric and monomeric expression in the PFC and hippocampus. mGluR5 protein expression in the PFC was strongly influenced by age (Total: F2,29 =  71.097, p < 0.001; dimer: F2,29 =  13.701,
p < 0.001). Total mGluR5 protein expression in the PFC peaked at PN12 in control rats, significantly declining at
PN35 (−64%, p < 0.001) with no significant difference between PN35 and PN96 (p = 0.189). While changes in
mGluR5 dimer expression in control rats between the developmental stages did not reach statistical significance
(F2,16 =  2.549; p = 0.114), post-hoc analyses combining the PCP and saline groups showed a significant reduction
in mGluR5 dimer from PN12-PN35 (p < 0.001) followed by an increase from PN35-96 (p = 0.021) back to PN12
levels. mGluR5 monomer expression in the PFC showed unequal variances between the groups (F5,27 =  20.022,
Scientific Reports | 6:34391 | DOI: 10.1038/srep34391
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Figure 2. mGluR1α protein expression is developmentally regulated in the PFC and hippocampus and is
reduced following perinatal PCP treatment. Relative total, dimeric and monomeric mGluR1αprotein levels
in the PFC (a–c) and hippocampus (d–f) of phencyclidine (PCP) treated rats compared to saline controls at
postnatal days (PN) 12, 35 and 96 (n = 5–6 per treatment/time point). Bars represent mean values. *p <  0.05,
**p < 0.01 and ***p < 0.001 indicate statistical significance between saline treated age groups. §p <  0.05 and
§§
p < 0.01 indicate statistical significance between perinatal PCP and saline treatment at specific age group.
Within the respective age groups the saline group is on the left (blue) and PCP treated group on the right (red).

Figure 3. mGluR5 protein expression reduces throughout development and is acutely increased following
perinatal PCP treatment in the PFC and hippocampus. Relative total, dimeric and monomeric protein levels
mGluR5 in the PFC (a–c) and hippocampus (d–f) of phencyclidine (PCP) treated rats compared to controls at
postnatal days (PN) 12, 35 and 96 (n = 5–6 per treatment/time point). Bars represent mean values. *p <  0.05,
**p < 0.01 and ***p < 0.001 indicate statistical significance between saline treated age groups. §p <  0.05 and
§§
p < 0.01 indicate statistical significance between perinatal PCP and saline treatment at specific age group. Bars
represent mean values + SEM. Within the respective age groups the saline group is on the left (blue) and PCP
treated group on the right (red).

p < 0.001) thus was analysed using non-parametric analyses. There was a significant age effect in control rats
(X2(2) =  11.014, p = 0.004); peak mGluR5 monomer levels occurred at PN12, followed by a dramatic reduction at
PN35 (−97%, U =  0.000, p < 0.001) with levels remaining low at PN96 (Fig. 3). While there were no main effects
of PCP treatment on mGluR5 total (F1,29 =  1.506, p = 0.230) or dimer (F1,29 =  0.035, p = 0.854), total mGluR5
expression in the PFC was influenced by an age x treatment interaction (F2,29 =  5.863; p = 0.007) in which perinatal
Scientific Reports | 6:34391 | DOI: 10.1038/srep34391
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Figure 4. Homer1b/c protein expression is unchanged following perinatal PCP treatment, but is
developmentally regulated. Relative protein levels of Homer1b/c in the (a) prefrontal cortex and
(b) hippocampus of phencyclidine (PCP) treated rats compared to controls at postnatal days (PN) 12, 35 and
96 (n = 5–6 per treatment/time point). Bars represent mean values. ***p < 0.001 indicate statistical significance
between saline treated age groups. Representative immunoblot images of Homer1b/c from saline (S) and
perinatal phencyclidine (P) treated rats at postnatal days (PN) 12, 35 and 96 in the prefrontal cortex (left) and
hippocampus (right) are shown below the graphs. Immunoblot values were normalised to β-actin. Homer1b/c
immunoblots produced a single band corresponding to its 48 kDa molecular weight. Within the respective age
groups the saline group is on the left (blue) and PCP treated group on the right (red).
PCP treatment increased total mGluR5 protein expression at PN12 compared to controls (37%, p =  0.002; Fig. 3).
This interaction was not observed for the mGluR5 dimer (F2,29 =  1.369; p = 0.270). Mann-Whitney testing revealed
that perinatal PCP treatment did not significantly influence mGluR5 monomer expression at any of the time points
investigated (PN12: U =  14.000, p = 0.522; PN36: U =  11.000, p = 0.754; PN96: U =  14.000, p =  0.931; Fig. 3).
mGluR5 protein expression in the hippocampus showed unequal variance (Total: F5,28 =  2.940, p =  0.029;
Dimer: F5,29 =  3.647, p = 0.011; Monomer: F5,28 =  10.273, p < 0.001), therefore non-parametric analyses were
employed. There were no significant effects of age on total (X2(2) =  2.020, p = 0.364) or dimeric (X2(2) =  4.833,
p = 0.089) mGluR5 expression. However, similar to the PFC, monomeric mGluR5 expression, showed a strong
effect of age (X2(2) =  24.939, p < 0.001; Fig. 3). Post-hoc analysis revealed that monomeric mGluR5 expression
peaked at PN12 in control rats followed by a significant decline at PN35 (−99%, U =  0.000, p < 0.001) and a modest increase from PN35 to PN96 (+441, U =  1.000, p = 0.011). Mann-Whitney tests revealed that perinatal PCP
treatment significantly increased total (50%, U =  0.000, p = 0.006) and dimeric (87%, U =  0.000, p =  0.009), but
not monomeric (U =  16.000, p = 0.818) mGluR5 expression at the PN12 time point (Fig. 3). No treatment effect on
mGluR5 expression (total, dimer or monomer) was observed at PN35 or PN96 (5 <  U <  16; 0.082 <  p <  0.0818).

Expression of Group I mGluR regulators, Homer1b/c and Norbin, in the PFC and hippocampus.

Homer1b/c levels in the PFC and hippocampus were significantly affected by age (PFC: F2,30 =  58.466; p <  0.001;
hippocampus: F2,30 =  80.713; p < 0.001). In both regions there was a significant increase in Homer1b/c levels
between PN12 and PN35 (PFC: 172%; p < 0.001; hippocampus: 113%; p < 0.001) and between PN12 and PN96
(PFC: 192%; p < 0.001; hippocampus: 108%; p < 0.001) (Fig. 4). There were no significant effects of PCP treatment on Homer1b/c levels (PFC: F1,30 =  0.909; p = 0.348; hippocampus: F1,30 =  0.744; p = 0.395) and no age x
treatment interactions (PFC: F2,30 =  0.025; p = 0.975; hippocampus: F2,30 =  1.095; p =  0.347).
Norbin levels in the PFC and hippocampus were also significantly affected by age (PFC: F2,30 =  4.506;
p = 0.019; hippocampus: F2,29 =  55.676; p < 0.001), with Norbin levels increasing from PN12 to PN96 in the PFC
(54%; p = 0.045) and between PN12 and PN36 (173%; p = 0.003) and PN12 to PN96 (219%; p < 0.001) in the hippocampus (Fig. 5). There were no effects of PCP treatment on Norbin expression (PFC: F1,30 =  0.477; p =  0.509;
hippocampus: F1,29 =  0.468; p = 0.499) and no age x treatment interactions (PFC: F2,30 =  0.588;p =  0.562; hippocampus: F2,29 =  1.892; p =  0.169).

Discussion

In this study, we report the neurodevelopmental profile of Group 1 mGluRs, including dimeric and monomeric
forms, in the PFC and hippocampus. Furthermore, we detailed the effects of perinatal PCP treatment, an established neurodevelopmental model of schizophrenia, on Group 1 mGluR protein expression in these brain regions.
Scientific Reports | 6:34391 | DOI: 10.1038/srep34391
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Figure 5. Norbin protein expression is unchanged following perinatal PCP treatment, but is
developmentally regulated. Relative protein levels of Norbin in the (a) prefrontal cortex and (b) hippocampus
of phencyclidine (PCP) treated rats compared to controls at postnatal days (PN) 12, 35 and 96 (n =  5–6 per
treatment/time point). Bars represent mean values. ***p < 0.001 indicate statistical significance between
saline treated age groups. C and D show representative immunoblot images of Norbin from saline (S) and
perinatal phencyclidine (P) treated rats at postnatal days (PN) 12, 35 and 96 in the prefrontal cortex (left) and
hippocampus (right) are shown below the graphs. Immunoblot values were normalised to β-actin. NB: Norbin
immunoblots produced a single band corresponding to its 75 kDa molecular weight. Within the respective age
groups the saline group is on the left (blue) and PCP treated group on the right (red).
Whilst mGluR1αand mGluR5 share similar structural and functional homology35, we report here that they
display differential monomeric and dimeric neurodevelopmental profiles and expression patterns following perinatal PCP treatment in rats. In view of the recent literature regarding mGluR-targeting compounds for the treatment of various psychiatric and neurodevelopmental disorders36, the present results may have implications for
the pharmacological profiles of these compounds at specific ages.
During development, total mGluR1αprotein and importantly its functional dimeric form, is relatively low in
the PFC and hippocampus following birth, with expression peaking at adolescence (hippocampus) or adulthood
(PFC). This is largely consistent with the one previous study examining dimeric and monomeric mGluR1α in
cortex and hippocampus10. mGluR5 dimer levels were relatively abundant and stable throughout the three stages
of development examined. Whilst mGluR5 monomers were expressed at the juvenile time point, they dramatically reduced at adolescence and adulthood, to the lowest limits of detection in both the hippocampus and PFC.
Further investigation is required to determine if this trend is specific to certain cell types. However, we also report
that this abundance of monomeric mGluR5 early in neurodevelopment is also present in the nucleus accumbens
region (see Supplementary Fig. S1), which is characterised by a vastly different neuronal population and neuronal
network than the PFC37 and hippocampus38 suggesting this finding is not brain region specific.
Previous studies have reported a more subtle reduction over time when examining total mGluR5 expression
in these regions7,10,39, however this is the first time the expression of the mGluR5 monomer has been reported
under non-reduced conditions, relative to the dimeric form during neurodevelopment. These dimeric and monomeric neurodevelopmental expression profiles may have implications for the mGluR pharmacological profiles
at specific ages. Positive allosteric modulators (PAMs), particularly targeting mGluR5, are being developed for the
potential treatment of schizophrenia36. mGluR5 PAMs bind within the 7-transmembrane membrane region of
mGluR5 and whilst exerting no G-protein activation alone when bound to dimers, PAMs are capable of potentiating glutamatergic signalling when glutamate is bound. In contrast, recent works from the Pin research team have
demonstrated that monomeric mGluRs are capable of G-protein activity, similar to that of a full agonist response,
in the presence of PAMs and the absence of glutamate12. This is important since glutamate-induced neurotoxic
effects and seizures have been observed following the use of Group 1 mGluR agonists40–42. The absence of the
monomer at adolescent and adult time points confers a potential advantage in avoiding these agonist-like effects
of mGluR5 PAMs. It is not known if the same abundance of monomeric mGluR5 is present in humans or at what
neurodevelopmental time point monomeric expression is reduced, however administration of mGluR5 PAMs at
a time point when monomeric mGluR5 is highly expressed may have adverse consequences. Further studies will
need to explore whether the abundant monomeric expression is capable of reaching the cell surface where it is
accessible to endogenous and exogenous targets. We investigated the Group I mGluR regulators Homer1b/c and
Norbin, which can regulate trafficking of mGluR5 to the cell surface26. Interestingly, these endogenous regulators
were in lower abundance at PN12 in both the PFC and hippocampus, at a time when there was high monomer,
suggesting possible differences in regulation and trafficking of mGluR5 at the different developmental stages.
Scientific Reports | 6:34391 | DOI: 10.1038/srep34391
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Perinatal PCP treatment substantially increased total mGluR5 expression in the PFC and hippocampus at
the juvenile time period, yet this did not extend to adolescence or adulthood time points. These findings are
consistent with postnatal administration of the NMDA receptor antagonist, MK-801, which increased mGluR5
mRNA expression in the cortex and hippocampus, 4 hrs post treatment43. Whilst the aforementioned study
did not investigate the long-term effect on mGluR5 mRNA or protein levels, Owaczarek et al., reported that
perinatal PCP treatment had no long term effect on mGluR5 protein levels in the PFC or hippocampus, when
measured at the single adulthood time point, consistent with our findings17. Together, these results suggest that
perinatal NMDA receptor antagonism may acutely upregulate cortical and hippocampal mGluR5 mRNA and
protein expression, but does not affect its long-term expression at adulthood. Despite inducing acute alterations
in mGluR5 expression, changes at such a critical neurodevelopmental period may have long-term consequences
on excitatory/inhibitory tone. Investigation of mGluR5 KO mice has shown mGluR5 activation critical for driving the normal neurodevelopmental NMDA receptor subunit, NR2B/2A switch44. The composition of NR2A/B
subunits plays an important role in the calcium dynamics of the NMDA receptor and synaptic plasticity45,46.
Although, we observed an increase in mGluR5 expression following perinatal PCP treatment, it is possible that
alterations in mGluR5 expression and/or activity during the juvenile neurodevelopmental period may consequently alter the development of NMDA receptor subunit composition, which has indeed been extensively
reported in this model14,15,17.
In contrast to mGluR5, the present study reported that total mGluR1αexpression was reduced in the juvenile hippocampus, of perinatal PCP treated rats. mGluR1αand mGluR5 share similar sequence and second
messenger coupling homology, although several studies have identified differences in their cellular location,
intracellular signalling and functionality47–49. In addition, we have shown in the present study that they have
differential dimeric and monomeric neurodevelopmental profiles, suggesting that the regulation of dimerization
may differ. Similar to mGluR5, mGluR1αis co-localised with the NMDA receptor and can modulate its activity50.
However, in contrast to mGluR5, which is abundantly found throughout the hippocampus and on various cell
types, mGluR1αmRNA and protein expression is found primarily in the CA1 region and localises to GABAergic
interneurons49,51–53. Hippocampal interneurons have previously been reported to be prone to insult and neuronal
death, following perinatal PCP treatment54 and reductions in hippocampal mGluR1αmay be a consequence of a
reduction in interneuron cell number. The results from the present study largely suggest that perinatal PCP treatment causes acute changes in mGluR1αand mGluR5 at the early stages of perinatal neurodevelopment, which
may contribute to altered glutamatergic signalling and neurodevelopmental abnormalities previously reported
in this model14,15,17.
In summary, we report that Group 1 mGluRs, mGluR1α and mGluR5, exhibit differential temporal and
regional neurodevelopmental expression patterns, especially in relation to dimeric and monomeric expression.
These findings may have implications for the effectiveness and side effect profile of mGluR PAMs at specific
developmental stages, however, pharmacological studies are required to investigate this. Furthermore, we show
that perinatal PCP treatment disrupts the normal developmental expression of these proteins in the PFC and
hippocampus, particularly at the juvenile period; this may contribute to ongoing developmental glutamatergic
alterations that are believed to contribute to the development of schizophrenia.

Materials and Methods
Animals.

Pregnant Sprague-Dawley rats were obtained at gestational day 14 from the Animal Resources
Centre (WA, Australia). Animals were housed under constant temperature control (20 °C) and 12:12 hour lightdark cycle. Rats were provided food and water ad libitum. Pups were sexed on post-natal day (PN) 7 and subsequently allocated into PCP or saline treatment groups. Dam and littermates were housed together until 3 weeks
of age, when they were weaned and housed 2/per cage of the same sex and treatment. Only female rats were used
in subsequent protein analyses in this study. This study was carried out in accordance with the Australian Code of
Practice for the Care and Use of Animals for Scientific Purposes (8th edition) and was approved by the University
of Wollongong Animal Ethics Committee (AE13/03).

Perinatal PCP Treatment. Female Sprague-Dawley rats were administered PCP (10 mg/kg, s.c.) (Sigma,
Castle Hill, Australia) or saline (0.9% NaCl) on PN7, 9 and 11. Rats were subsequently euthanised by carbon
dioxide asphyxiation and decapitation on PN12, 35 and 96 (n = 6/group) coinciding with juvenile, adolescent
and adult time points as previously described in Du Bois et al.,15,31. The prefrontal cortex and hippocampus were
dissected according to a standard rat brain atlas55, snap frozen in liquid nitrogen and stored at −80 °C.
Rat Brain Tissue Preparation. Tissue samples (left and right hemispheres combined) were homogenised
in buffer containing 0.1 M Tris-HCl, 2 mM EDTA, 10% glycerol, 2% SDS, 100 mM iodoacetamide, 0.5 mM PMSF,
Protease Inhibitor Cocktail (P8340; Sigma, Australia) and Phosphatase Inhibitor Cocktail 2 (Sigma, Australia).
Samples were then centrifuged at 10 000 g for 10 minutes at 4 °C, supernatant collected and stored at −8 0 °C. Total
protein concentration was determined using a DC assay kit as per the manufacturer’s instructions (Bio-Rad,
Australia).
Immunoblotting.

Equal amounts of protein (2.5 ug/well) were separated in 4–20% TGX precast gels
(Bio-Rad, Australia) under non-reducing conditions to promote the integrity of mGluR homodimers. Proteins
were subsequently transferred onto PDVF membranes (Bio-Rad) and membranes blocked with 5% BSA or
skim milk (w/v) for 60 minutes at room temperature. The membranes were incubated overnight in the primary polyclonal antibodies at the following concentrations: anti-mGluR1α(1:15000; D5H10, Cell Signalling),
anti-mGluR5 (1:5000; ab29170, Abcam), anti-Neurochondrin (1:7500; ab130507, Abcam) and anti-Homer1b/c
(1:7500; ab211415, Abcam). Membranes were subsequently incubated with horseradish peroxidase conjugated
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secondary antibodies (1:5000; AP307P, Millipore). Bands were visualised using Amersham ECL western blotting detection reagent (GE Healthcare, Australia) and membranes exposed to Hyperfilm (GE Healthcare,
Australia). Exposure times were reliant on obtaining optimal images to quantify Group 1 mGluR dimeric and
monomeric bands. Films were scanned using a GS-800 scanner (Bio-Rad) and densitometry values were quantified. Relative densitometry values for each protein were normalised to their respective β-actin levels and an
internal control value, to account for protein loading and gel-gel variability, respectively. Each sample was run
in duplicate.

Statistical Analysis. Two-way Analyses of Variance (ANOVA) were used to determine any effects of age
and treatment on relative protein densities. Where significant interactions were found, independent t-tests
were used to identify differences between treatment groups at specific ages. One-way ANOVAs were used to
determine significance between age groups within the control group only. While all data showed a normal
distribution (Kolmogorov–Smirnov p > 0.05), normality testing can be unreliable in small samples56. However,
given the findings from the KS test coupled with the observation that biological variables tend to be normally
distributed57, statistical analyses were completed using parametric analyses as per Dean et al.58 and our previous studies15. However, where there were unequal variances between the groups (mGluR5 monomer in the
PFC, mGluR5 total, dimer and monomer in the hippocampus), non-parametric analyses were employed.
Kruskall-Wallis tests were used to determine the significance between age groups within the control groups.
Mann-Whitney U tests were used to determine the effect of PCP treatment at specific ages. Significance was set
at an alpha level of p = 0.05.
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